JAMA Network reports VESALIUS-CV results suggesting evolocumab plus statin reduced first major cardiovascular events in people with diabetes without known significant atherosclerosis, supporting more intensive LDL-C lowering in selected patients.
Evolocumab for Heart Protection in People With Diabetes
intensive LDL-C lowering with evolocumab plus statin reduced risk of first major cardiovascular event vs placebo
VESALIUS-CV trial
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare